To access this element change to forms mode OFF
Grant Award View - GA268492
Experimental Validation of the Target of ESFAM289 - a molecule with in...
GA ID:
GA268492
Agency:
Department of Health and Aged Care
Approval Date:
19-Jun-2022
Publish Date:
4-Oct-2022
Category:
Medical Research
Grant Term:
19-Jun-2022 to 31-May-2026
Value (AUD):
$1,100,000.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
Experimental Validation of the Target of ESFAM289 - a molecule with in vivo efficacy against SARS-CoV-2
Purpose:
Esfam has identified a molecule, ESFAM289, which has been demonstrated to be an effective treatment for COVID-19 in small animal studies. This project will generate data necessary to enable the commencement of clinical trials including information on how the molecule binds to its potential target and how it interrupts COVID-19 infection.
GO ID:
GO Title:
MRFF – CRR – 2021 COVID-19 Treatment Access and Public Health Activities Grant Opportunity
Internal Reference ID:
2022/MRF2017822
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Esfam Biotech Pty Ltd
Recipient ABN:
81 614 394 482
Grant Recipient Location
Suburb:
Heidelberg
Town/City:
Heidelberg
Postcode:
3084
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA